Results - Announcements
Ind-Swift Laboratories Ltd share price headed higher 7.75% to Rs 408.85 after the company's net profit jumped 38.99% to Rs 34.15 crore, while revenue from operations increased sharply by 25.60% to Rs 240.46 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, rising 4.44%. It has improved by 5.74% over last one week and moved up slightly by 0.60% in last one month while the market capitalization of Ind-Swift Laboratories Ltd has significantly gained 24.73% and 81.87% in the same period respectively.
Profit before tax (PBT) of Ind-Swift Laboratories Ltd stood at Rs 43.38 crore in Q3 FY26, surging by 319.54% year-on-year, and expanding by 33.23% quarter-on-quarter. EBITDA came in at Rs 38 crore, tumbling by 962.41% YoY and rallying 46.86% sequentially.
Total expenses witnessed a sharp rise of 22.45% to Rs 202.77 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 92.87 crore, going up by 13.59% YoY, while employee benefits expense was at Rs 37.97 crore, slipping by 4.02% YoY.
For the TTM ended FY26, revenue from operations advanced 15.56% to Rs 649.14 crore, while net profit witnessed a sharp fall of 82.82% to Rs 43.03 crore, compared to previous TTM. EBITDA tumbled by 9564% to Rs 0.16 crore, and PBT tanked by 80.31% to Rs 50.76 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 68.17 crore in FY26, as against Rs 28.69 crore in FY25.
Ind-Swift Laboratories Ltd soared by 297.52% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 12.76% during the same period.